UCB boards T cell engager train Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 4 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by The $50K-a-day prob­lem in clin­i­cal tri­al en­roll­ment

news Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant Sanofi licenses Sino Biopharm's 'breakout star' transplant drug for $135M upfront UCB boards T cell engager train in $60M upfront deal with Antengene Blackstone to support Teva on Sanofi-partnered TL1A with $400M Kyowa Kirin ends OX40 trials after Amgen balked and more safety concerns arose

Mar 24 11:30 am ET From structure to selectivity: Federated AI for collaborative binding affinity prediction sponsored by Rhino Federated Computing

Register to see thought-leaders across pharma and biotech present innovation strategies for drug development and new partnership and licensing opportunities to advance these concepts. sponsored by American Association for Cancer Research

endpoints pharma In reversal, Prime Medicine will seek FDA approval of previously shelved gene therapy FDA explains how some copycat drugs can still win three years of exclusivity After years of dispute with FDA, Vanda will get a public hearing for jet lag drug ICER calls on CMS to lower price of Takeda blockbuster Entyvio to Stelara's level Corrected: Hims’ pharmacy partner won’t reintroduce GLP-1 pill pulled from market

in case you missed it 1. Exclusive: EveryOne Medicines shuts down, ending custom cure venture that banked on new FDA pathway 2. Theravance ends R&D, lays off half of workforce after repeated Phase 3 fails 3. Boehringer Ingelheim tried to use a tempting, tough cancer target for liver disease. It didn’t work 4. News Briefing Prolium's $50M Series A raise; COUR Pharma touts liver drug follow-up 5. Esperion to buy Corstasis and its nasal spray for edema for $75M upfront 6. US FDA warns Novo again about misleading drug advertising 7. Bayer Forecasts Flat 2026 Profits Amid Roundup Settlement Effort